The combination of umbralisib plus ublituximab, often abbreviated to U2, has promising activity in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) as shown in this ASH 2021 abstract:
Ask the Lab Scientist Question: Do you know of any ongoing clinical trial that is studying the seronegative response of COVID antibodies after the vaccination? I have read that it is
Dr. Brian Koffman spoke with Dr. Kerry Rogers, assistant professor and hematologist in the Division of Hematology at the Ohio State University, about an upcoming phase I clinical trial of VIP152, a new cyclin-dependent kinase 9 (CDK9) inhibitor for patients with double refractory CLL or Richter syndrome.
Clinical Trial Phases, the Drug Approval Process, and Measuring Responses In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are
This clinical trial introduces the concept of “synthetic lethality,” where multiple targeted agents are used at low dosages to block different pathways, and achieve the ability to kill cancer cells without the associated toxicities of using three drugs together at their usual dosages.
There has been much excitement about the possibility that BTK inhibitors such as ibrutinib or acalabrutinib might improve outcomes in COVID-19 for all patients ever since Dr. Treon published a retrospective
In this ASH 2019 interview with Dr. Brian Koffman, Dr. Debbie Stephens discusses her clinical trial combining Selinexor with ibrutinib for patients who have become refractory to ibrutinib.
A video interview between Terry Evans, CLL patient and Sheila Hoff, RN, Clinical Trial Nurse at the University of California, San Diego, Moores Cancer Center. (See video at the bottom of
New novel agents are being tested in clinical trials to help patients with CLL who have developed resistance to all the BTK inhibitors and BCL2 inhibitors.
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911
